Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 576 to 600 of 1160 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
585 decreased carboxylation reaction (MI:1139) coagulation factor X (mouse) (PR:O88947) 1131: Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin)
584 decreased carboxylation reaction (MI:1139) coagulation factor IX (mouse) (PR:P16294) 1131: Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin)
583 decreased carboxylation reaction (MI:1139) coagulation factor VII (mouse) (PR:P70375) 1131: Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin)
582 decreased carboxylation reaction (MI:1139) prothrombin (PR:000007299) 1131: Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin)
581 abnormal wound healing (GO:0042060) 1130: Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)
580 abnormal hemostasis (GO:0007599) 1122: Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis
579 increased reactive oxygen species (CHEBI:26523) None
578 abnormal role (MESH:D012380) 1108: Abnormal, Role change within caste
577 increased Viral load (MESH:D019562) 1109: Increased, Deformed Wing Virus levels
576 occurrence ischemia (MESH:D007511) kidney (UBERON:0002113) 1105: Occurrence, renal ischemia
575 increased 3,3',5-triiodo-L-thyronine (CHEBI:18258) 1116: Decreased, Triiodothyronine (T3) in tissues
574 increased metamorphosis (GO:0007552) 1101: Altered, Amphibian metamorphosis
573 increased mesothelioma (MESH:D008654) None
572 increased cell proliferation (GO:0008283) mesothelium (UBERON:0001136) 1089: Increased, Cell Proliferation (mesothelium)
571 increased cell death (GO:0008219) pleura (UBERON:0000977) 1086: persistent, cytotoxicity (pleura or peritoneum)
570 increased hyperplasia (MESH:D006965) mammary gland (UBERON:0001911) 1085: Increased, hyperplasia (mammary gland)
569 increased prolactin secretion (GO:0070459) prolactin (PR:000013246) 1084: Increased, prolactin secretion
568 increased synaptic transmission, dopaminergic (GO:0001963) dopaminergic neuron (CL:0000700) 1083: Decreased, Dopaminergic activity
567 increased Pituitary adenoma (HP:0002893) Adenoma (MESH:D000236) 1082: Increased, adenomas (pituitary)
566 increased hypertrophy (MESH:D006984) prolactin secreting cell (CL:0000439) 1081: Increased, lactotroph hyperplasia and hypertrophy
565 increased hyperplasia (MESH:D006965) prolactin secreting cell (CL:0000439) 1081: Increased, lactotroph hyperplasia and hypertrophy
564 increased abnormal tumor latency (MP:0010307) 1080: Increased, latency period
563 increased mammary gland hyperplasia (MP:0000630) 1078: Hyperplasia, Mammary gland
562 increased prolactin (PR:000013246) 1077: Increased, prolactin exposure
561 increased estrogen (CHEBI:50114) 1076: Increased, circulating estrogen levels